• support@madhedgefundtrader.com
  • Member Login
Mad Hedge Fund Trader
  • Home
  • About
  • Store
  • Luncheons
  • Testimonials
  • Contact Us
  • Click to open the search input field Click to open the search input field Search
  • Menu Menu
MHFTR

The Real Estate Crash Coming to a Market Near You

Diary, Newsletter, Research

Hardly a day goes by when a reader doesn’t ask me when the Australian real estate bubble is going to burst.

They are right to be concerned.

In the table below, Sydney is ranked as the second most expensive market in the world at 12.2 times the local median pre-tax household annual income.

It is far behind Hong Kong, at 19.9 times, and just ahead of Vancouver, Canada, at 10.8 times.

Even Australian banking regulators are concerned about a “Dutch tulip” style mania developing in the Land Down Under.

They are worried that the coming price collapse will pose a major threat to their financial system.

Indeed, a home on Sydney Harbor owned by my former employer, the Fairfax newspaper family, sold for a staggering AUS$75 million, a new record for the country.

Sure, the views are great. But AUS$75 million?

I have been through a lot of these real estate booms over the past five decades.

There was the notorious Japanese bubble in 1990. I have been through at least three such booms in California. Here, real estate brokers can turn into Uber drivers in a heartbeat.

And they always follow the same predictable pattern.

How high is high? Think of an absurd, impossible number, and then double it. That always seems to be a good rule of thumb. Except that Australia is already past that last doubling.

When my Australian friends ask how high prices can go, I tell them to check out prices in Shanghai, where apartments go for twice as high for a quarter of the space.

In fact, identifying bubble tops is a fool’s errand. When markets become irrational, the last thing buyers care about is rationality, hard data, or valuations.

In the past, the music always stopped playing for the same reasons.

Central banks fearful of inflation slammed on the brakes and drove interest rates through the roof, as Paul Volker did in 1980.

An extraneous shock, such as the 1973 and 1979 oil price spikes or the 1991 Savings & Loan Crisis, can also let the air out of the balloon.

I remember that during the S&L Crisis, I was ushered in to see a California property, and the owner burst into tears when the agent mentioned the price because of the huge personal hit he was taking on his equity.

Except that this time, it’s different.

Real estate used to be local. Now, it’s global.

You have the same factor pushing up property in prime markets all over the world at the same time: Chinese buying.

For a decade now, buyers from the Middle Kingdom have been bidding up the prices of homes in London, Australia, New York, Vancouver, and elsewhere.

You know that nice little mansion I sold in London in 1994 for $2 million? It’s now worth $20 million.

In nearby Napa Valley, CA, the Chinese are snapping up trophy vineyards left and right, paying wildly inflated prices. Prices are up an eye-popping 16.6% year on year.

You can always tell when a property changes hands when the stone lions show up at the front gates.

Their goal is the same everywhere. Get their money out of China before the wheels fall off, be it for economic or political reasons.

The Chinese aren’t looking for retirement homes. They need bolt-hole places to hide out.

A stepped-up anti-corruption campaign by the Beijing government seems to have accelerated the trend.

The capital flows have been so enormous that the Chinese government has had to liquidate $1 trillion in foreign exchange reserves, a quarter of the total, primarily held in US Treasury bonds, notes, and bills, to support the Renminbi.

These gargantuan capital flows have created the same anomalies around the world, that of “ghost neighborhoods” owned for investment purposes only.

On the receiving end, the US government is taking measures to stem money laundering and tax evasion.

The IRS is using the Patriot Act to require proof of ownership for all real estate purchases over $2 million in New York and San Francisco.

Cayman Islands, British Virgin Islands, and Cook Islands nominee holding companies or LLC’s can no longer be used as identity shields.

Without real residents living there, local businesses, like dry cleaners, coffee shops, and supermarkets, die off for lack of customers.

Take a walk around the Mayfair district of London one of these days, and you’ll see what I mean.

Or ride up and down the elevators in the residential towers at New York’s Columbus Circle, where 60% of the apartments are foreign-owned.

I even have one of these at the end of my street here in San Francisco.

The home came on the market for $2.1 million three years ago and sold in a day for $2.3 million. It has been empty ever since.

(By the way, the opposite end of my street displays San Francisco’s other big problem, start-ups moving into cheaper residences to avoid sky-high commercial property rates. There, the lights NEVER go out.)

Real estate agents everywhere love the business.

Most of these deals are done for cash only with rushed due diligence. Loan approvals and appraisals, frequent deal killers for domestic buyers, never even enter the picture.

For the sake of full disclosure, I have to admit that I have been a happy participant in the property gold rush like everyone else, making a kings ransom on properties I bought during the 2011 bottom, at least on paper.

Look at the table below, and you’ll see that four of the world’s ten most expensive cities are in California. Perhaps I shouldn’t throwing stones in glass houses.

But at least here, you have multiple booms going on in technology, health care, alternative energy, and transportation, driving earnings, and, therefore, house prices.

Since the causes of this bubble are largely come from China, so must the end.

A serious economic slowdown in China would tip the balance. So would a trade war with the US.

Tougher controls on capital flows could stem the tide. So would political instability, never far below the surface in China.

Whatever the reason, leveraged owners of luxury real estate anywhere on the planet should always keep one thing in mind: Your fate is totally in the hands of China.

https://www.madhedgefundtrader.com/wp-content/uploads/2018/04/Worlds-least-affordable-cities-story-1-image-1-e1523486486630.jpg 402 580 MHFTR https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png MHFTR2024-11-27 09:04:142024-11-27 11:40:40The Real Estate Crash Coming to a Market Near You
april@madhedgefundtrader.com

Tech Alert - (NFLX) November 26, 2024 - BUY

Tech Alert

When John identifies a strategic exit point, he will send you an alert with specific trade information as to what security to sell, when to sell it, and at what price. Most often, it will be to TAKE PROFITS, but on rare occasions, it will be to exercise a STOP LOSS at a predetermined price to adhere to strict risk management discipline. Read more

https://www.madhedgefundtrader.com/wp-content/uploads/2016/02/Alert-e1457452190575.jpg 135 150 april@madhedgefundtrader.com https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png april@madhedgefundtrader.com2024-11-26 14:36:332024-11-26 14:36:33Tech Alert - (NFLX) November 26, 2024 - BUY
april@madhedgefundtrader.com

November 26, 2024

Biotech Letter

Mad Hedge Biotech and Healthcare Letter
November 26, 2024
Fiat Lux

 

Featured Trade:

(NO MORE EATING AT YOU)

(PFE), (LLY), (NVO), (AMGN), (RYTM), (ALT)

https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png 0 0 april@madhedgefundtrader.com https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png april@madhedgefundtrader.com2024-11-26 12:02:442024-11-26 12:05:20November 26, 2024
april@madhedgefundtrader.com

No More Eating At You

Biotech Letter

In 1903, the original “diet miracle” was invented—tapeworm pills. Yes, people willingly ingested parasites to lose weight.

Thankfully, modern weight-loss drugs have evolved to become a bit more... palatable. Enter Pfizer (PFE), taking the pharmaceutical stage in Q3 2024 with a performance that’s anything but parasitic.

Pfizer just reported a stunning $17.7 billion in Q3 2024 revenue—a 31% year-over-year increase that has nothing to do with parasites and everything to do with strategic positioning.

But here's where it gets interesting. Even if you strip away Pfizer's COVID-19 products (which, let's face it, had their moment like platform shoes in the '70s), they're still sitting pretty with $13.6 billion in revenue.

That's a 14% operational increase that has nothing to do with our old friend coronavirus.

Meanwhile, in the weight-loss corner of the ring, Eli Lilly (LLY) and Novo Nordisk (NVO) are experiencing what we might delicately call "growing pains."

Eli Lilly reported $11.44 billion in Q3 revenue—impressive until you consider analysts expected $12.18 billion.

Novo Nordisk's story is even more peculiar. Their weight-loss wonder drug Wegovy is selling like hotcakes (irony noted) at 17.3 billion Danish krone (about $2.75 billion USD).

But here's the catch: Novo Nordisk can't make enough of it. It's the pharmaceutical equivalent of having a hit restaurant where half the menu items are perpetually "sold out."

This shortage highlights just how insatiable the market's appetite for these drugs has become.

In 2023 alone, the US market for prescription weight-loss drugs more than doubled from $5.1 billion to $11.9 billion.

Gone are the days of dubious diet pills and miracle cures. We're witnessing the dawn of scientifically backed weight management solutions.

As for Pfizer, they’re not content to watch from the sidelines. They're developing something called danuglipron (a name that sounds like it was conceived during a particularly intense game of Scrabble). It's an oral weight-loss drug currently in Phase 2B trials.

Danuglipron’s key selling point? It's an oral medication—no needles required.

As someone who once spent three months investigating the science of injection phobia for a story, I can confirm this detail matters more than you might think.

Pfizer’s plans go beyond just one drug. In the first 9 months of 2024, they invested $7.8 billion in R&D.

Their recent acquisition of Seagen has already contributed $854 million in Q3 2024 revenue, proving that their strategy of buying innovation is paying off.

In fact, they're so confident about their trajectory that they've raised their full-year 2024 revenue guidance to between $61 billion and $64 billion.

But let's talk about the elephant in the pharmacy – regulatory approval. The FDA, bless their bureaucratic hearts, has been keeping everyone on their toes with their evolving stance on weight-loss drugs and other treatments.

Still, Pfizer managed to snag approvals for two new drugs in October 2024: Abrysvo (for RSV in adults) and Hympavzi (for hemophilia).

Both approvals came through in October 2024, showing off Pfizer’s ability to navigate modern pharmaceutical regulations.

Looking globally, the weight loss and obesity management market is projected to grow from $14.51 billion in 2024 to $48.39 billion by 2034.

Of course, no good pharma story is complete without a plot twist. Pfizer's oncology drug Ibrance saw a 12% operational decrease in Q3 2024 revenue, reminding us that even pharmaceutical juggernauts can stub their toes.

And those patents? They're like time bombs ticking away in the legal department's filing cabinet.

The obesity field is attracting new players, too. Amgen (AMGN) is developing MariTide, while Rhythm Pharmaceuticals (RYTM) focuses on genetic obesity disorders.

Altimmune's (ALT) pemvidutide is showing promising Phase 2 results, adding to the increasingly crowded field of weight-loss treatments.

So, where should you park your money? Here’s a quick guide to the stocks worth scooping up when the market takes a breather.

Novo Nordisk remains the heavyweight champion of weight-loss drugs, with Wegovy and Ozempic bringing in the big bucks. Yes, they're wrestling with production issues, but their first-mover advantage and global reach make them a solid buy for the long haul.

Eli Lilly, with Mounjaro and the freshly minted Zepbound, deserves a spot in your portfolio too. Their supply chain headaches are likely temporary, and their pipeline is bursting with potential.

Pfizer, our surprising comeback kid, rounds out the list. They might be fashionably late to the weight-loss party, but their diversification strategy and that promising GLP-1 pill in development make them worth your investment dollars. Plus, their global reach could give them an edge against their competitors.

On the hold list, we’ve got Amgen and Rhythm Pharmaceuticals—stocks you might want to keep an eye on but not necessarily dive into headfirst just yet.

Amgen's MariTide shows promise, but they're playing in a very crowded pool. Rhythm's focus on genetic obesity disorders is fascinating, but they're like a promising indie band - they might hit it big, or they might not.

As for Altimmune and Viking Therapeutics? Sometimes you need to know when to fold 'em. Despite promising early results, they're up against giants with deeper pockets and better-established supply chains.

Unless you enjoy roller coasters without safety bars, consider redirecting those investment dollars elsewhere.

Looking back, we've come an astonishingly long way from those desperate days of tapeworm pills—turns out the real money wasn't in selling parasites, but in pioneering their prescription-strength replacements.

And that's the kind of progress that would make those 1903 tapeworm salesmen drop their jaws (and hopefully nothing else).

 

https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png 0 0 april@madhedgefundtrader.com https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png april@madhedgefundtrader.com2024-11-26 12:00:442024-11-26 12:05:02No More Eating At You
april@madhedgefundtrader.com

November 26, 2024

Diary, Newsletter, Summary

Global Market Comments
November 26, 2024
Fiat Lux

 

Featured Trade:

(TRADING THE KENNEDY ASSASSINATION)

https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png 0 0 april@madhedgefundtrader.com https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png april@madhedgefundtrader.com2024-11-26 09:04:552024-11-26 10:31:03November 26, 2024
Arthur Henry

November 26, 2023 - Quote of the Day

Diary, Newsletter, Quote of the Day

"Ask not what your country can do for you, but what you can do for your country," said John F. Kennedy, America's 35th president.

 

https://www.madhedgefundtrader.com/wp-content/uploads/2014/11/John-F.-Kennedy.jpg 246 248 Arthur Henry https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png Arthur Henry2024-11-26 09:00:542024-11-26 10:30:44November 26, 2023 - Quote of the Day
Douglas Davenport

Amazon Doubles Down on AI with Another $4 Billion Investment in Anthropic

Mad Hedge AI

Amazon has once again shaken the artificial intelligence landscape, announcing a second tranche of $4 billion in funding for Anthropic, the rapidly growing AI startup. This substantial investment, mirroring the initial $4 billion commitment made just over a year ago, underscores Amazon's aggressive pursuit of a leading role in the burgeoning field of generative AI.

Anthropic, founded by former OpenAI researchers, has rapidly gained recognition for its Claude family of large language models. These models are increasingly seen as powerful contenders to OpenAI's ChatGPT, offering comparable capabilities in natural language processing, text generation, and code creation.

This latest investment builds upon an already strong partnership between the two companies. Anthropic has designated Amazon Web Services (AWS) as its primary cloud provider and training partner, leveraging AWS's extensive infrastructure, including its custom-designed Trainium and Inferentia chips, to train and deploy its increasingly complex and demanding AI models.

"We are deeply impressed by Anthropic's relentless pace of innovation and their steadfast commitment to the responsible development of generative AI," said Matt Garman, CEO of AWS, in a blog post announcing the investment. "This expanded collaboration allows us to further push the boundaries of what customers can achieve with generative AI technologies, driving transformative change across industries."

A Strategic Alliance with Far-Reaching Implications

This deepened collaboration holds significant implications for both companies and the broader AI ecosystem:

  • Fueling Anthropic's Growth: The influx of capital will undoubtedly accelerate Anthropic's research and development efforts. This will allow them to refine their existing models, explore new AI architectures, and expand the capabilities of Claude, potentially surpassing current industry benchmarks in areas like reasoning, code generation, and creative content creation.
  • Strengthening AWS's AI Arsenal: By investing in Anthropic, Amazon secures privileged access to cutting-edge AI technology. This strengthens AWS's position as a leading cloud provider for AI workloads, attracting businesses and developers seeking to leverage the power of generative AI. The deal also includes early access for AWS customers to fine-tune Anthropic's models with their own data, enabling the creation of highly customized AI solutions.
  • Accelerating AI Adoption: This partnership is poised to democratize access to advanced AI technologies. By making Anthropic's models readily available through AWS, businesses of all sizes can harness the power of generative AI to automate tasks, gain insights from data, and develop innovative products and services.
  • Promoting Responsible AI Development: Both Amazon and Anthropic have emphasized their commitment to responsible AI development. This includes prioritizing safety, fairness, and transparency in their AI systems. By collaborating, they can share best practices and contribute to industry-wide efforts to mitigate the potential risks associated with AI.

Competition Heats Up in the Generative AI Arena

This significant investment comes amidst a fierce battle for dominance in the generative AI space. OpenAI, backed by Microsoft, remains a major player with its widely adopted ChatGPT. Google, with its powerful Gemini family of models, is also a formidable competitor. Other players, including Meta and Stability AI, are vying for market share with their own innovative AI offerings.

Amazon's continued investment in Anthropic signals its determination to be a major force in this rapidly evolving landscape. By aligning with a leading AI startup, Amazon gains access to cutting-edge technology and talent, while Anthropic gains the resources and infrastructure needed to scale its operations and compete effectively.

Beyond the Hype: Real-World Applications

While the immense potential of generative AI is still being explored, early applications are already emerging across various sectors:

  • Healthcare: AI models like Claude can assist in medical research, drug discovery, and patient diagnostics, potentially revolutionizing healthcare delivery.
  • Software Development: AI tools can automate code generation, assist in debugging, and accelerate software development cycles.
  • Customer Service: AI-powered chatbots can provide instant support, answer customer queries, and personalize interactions.
  • Content Creation: Generative AI can assist in writing, translating, and summarizing text, as well as generating images, music, and other creative content.
  • Education: AI tutors can provide personalized learning experiences, adapt to individual student needs, and enhance educational outcomes.

As the technology matures and becomes more accessible, we can expect even more innovative and transformative applications to emerge, reshaping industries and redefining the way we work and live.

The Road Ahead

Amazon's renewed commitment to Anthropic signifies a long-term strategic bet on the future of AI. This partnership is poised to accelerate the development and deployment of advanced AI systems, driving innovation and fueling competition in the generative AI space. As these technologies continue to evolve, we can anticipate a future where AI plays an increasingly integral role in our lives, transforming industries, augmenting human capabilities, and unlocking new possibilities.

 

https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png 0 0 Douglas Davenport https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png Douglas Davenport2024-11-25 16:26:402024-11-25 16:26:40Amazon Doubles Down on AI with Another $4 Billion Investment in Anthropic
april@madhedgefundtrader.com

November 25, 2024

Tech Letter

Mad Hedge Technology Letter
November 25, 2024
Fiat Lux

 

Featured Trade:

(TECH STOCKS COULD ENTER A RENAISSANCE)
(NVDA), (TSLA), ($COMPQ)

https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png 0 0 april@madhedgefundtrader.com https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png april@madhedgefundtrader.com2024-11-25 14:04:532024-11-25 15:57:18November 25, 2024
april@madhedgefundtrader.com

Tech Stocks Could Enter A Rennaisance

Tech Letter

The consensus of AI and robotics only taking “blue-collar” jobs is now steadily morphing into a new type of rhetoric.

It was once seen that heavy labor, like Amazon’s robots hauling away heavy items in a warehouse, was the widespread case for robots and AI.

However, I’ve been talking to many industry experts who have privately confided that it could be white-collar jobs that receive the most dramatic cuts.

Think about it, can AI and a robot really do the same job as an HVAC repairman or even a plumber?

If tech is able to solve that level of complexity, then the sky is the limit for tech, but I don’t believe we are anywhere near that yet. It is more likely that people typing simple code into computers will be swapped out for an algorithm, which would be an easy one-to-one switch. Jobs that don’t require a physical presence will always be first in line to be cut.

AI has proven that it operates with limited common sense or street smarts, and in some jobs, these 2 skills are essential to performing well.

By analyzing over 24,000 AI-related patents filed between 2015 and 2022, the researchers were able to identify which occupations might be most affected by emerging AI technologies.

Surprisingly, some of the occupations with the highest scores were white-collar jobs requiring advanced education and specialized skills. Topping the list were cardiovascular technologists and technicians, sound engineering technicians, and nuclear medicine technologists. Other jobs at high risk of automation included air traffic controllers, magnetic resonance imaging (MRI) technologists, and even neurologists.

In the information technology sector, 47% of software developers’ tasks and 40% of computer programmers’ tasks were found to align closely with recent AI patents. These patents focused on automating programming tasks and developing workflows, suggesting that even highly skilled tech jobs may not be immune to AI’s influence.

The least likely to be impacted by AI in the near future tended to be blue-collar jobs requiring physical labor or manual dexterity, such as pile driver operators, dredge operators, and aircraft cargo handling supervisors.

Just looking at the new increases in amount of robots suggests that job replacement is coming thick and fast.

Slightly more than 10% of South Korea's workforce has been replaced with robots.

The country has increased its use of robots by 5% each year since 2018.

China, with 470 robots per 10,000 employees, has overtaken Germany and Japan and landed in third place behind Singapore.

The United States ranked 10th with 295 robots per 10,000 employees.

North America's robot density is 197 units per 10,000 employees – up 4.2%.

America has lost around half a million jobs to robots so far, but I believe this concept isn’t linear, and we won’t be able to just extrapolate our current trends into the future.

Once it rains, it will really pour.

It is no coincidence that software companies are firing software engineers in large groups. Silicon Valley has really trimmed the fat off the boat, taking the cue from Elon Musk firing 80% of Twitter and functioning meaningfully better.

I come back to this concept of tech companies operating with algorithms powered by AI with a few “managers” and executives.

We aren’t a few days or months from this coming to fruition, but we are years.

The complete overhaul in staff numbers would mean that tech stocks would enjoy a renaissance and rise 5X to 10X from today’s levels to the joy of shareholders.

American society has never held such a high portion of its wealth in tech stocks, and that will continue as tech stocks get bid up and tech companies doing anything under the sun to massage the stock higher.

 

https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png 0 0 april@madhedgefundtrader.com https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png april@madhedgefundtrader.com2024-11-25 14:02:412024-11-25 15:57:06Tech Stocks Could Enter A Rennaisance
april@madhedgefundtrader.com

November 25, 2024

Jacque's Post

 

(INVESTORS ARE LOOKING FOR CLARITY ON THE PATH OF INTEREST RATES IN THANKSGIVING WEEK)

November 25, 2024

 

Hello everyone

 

WEEK AHEAD CALENDAR

 

MONDAY NOV. 25

8:30 a.m. Chicago Fed National Activity Index (October)

Earnings: Agilent Technologies

 

TUESDAY NOV. 26

8:00 a.m. Building Permits final (October)

9:00 a.m. FHFA Home Price Index (September)

9:00 a.m. S&P/Case -Shiller comp. 20 HPI (September)

10:00 a.m. Consumer Confidence (November)

10:00 a.m. New Home Sales (October)

10:00 a.m. Richmond Fed Index (November)

2:00 p.m. FOMC Minutes

8:00 p.m. New Zealand Rate Decision

Previous: 4.7%

Forecast: 4.25%

Earnings: HP, Dell Technologies, CrowdStrike, NetApp, J.M. Smucker, Analog Devices, Best Buy, Autodesk

 

WEDNESDAY NOV. 27

8:30 a.m. Durable Orders (October)

8:30 a.m. GDP second preliminary (Q3)

8:30 a.m. Initial Claims (11/23)

8:30 a.m. Personal Income (October)

8:30 a.m. Wholesale Inventories preliminary (October)

10:00 a.m. PCE Deflator (October)

10:00 a.m. Pending Home Sales Index (October)

10:00 a.m. Pending Home Sales (October)

 

THURSDAY NOV. 28

8:30 a.m. Continuing Jobless Claims (11/16)

6:30 p.m. Japan Unemployment Rate

Previous: 2.4%

Forecast: 2.5%

Events: NYSE closed for Thanksgiving Day

 

FRIDAY NOV. 29

2:00 a.m. Canada GDP Growth

Previous: 0.5%

Forecast: 0.4%

9:45 a.m. Chicago PMI (November)

Events: NYSE closes 1:00 p.m.

 

WHAT’S ON THE RADAR THIS WEEK?

Interest rate outlook will take centre stage this week with key inflation data Federal Reserve meeting minutes coming out ahead of Thanksgiving.

The October personal consumption expenditure (PCE) price index set to be released Wednesday may give further insight into the likelihood of a rate cut in December.  Many economists are expecting that the PCE may show sticky inflation. It looks like the last stretch to a 2% inflation target could be very challenging.

The FOMC minutes for the November meeting will be closely watched by investors.  They want to know what the Fed’s path going forward is regarding interest rates.  Are they still committed to interest rate cuts?  If investors are confident that the Fed remains committed to further cuts, the investment case for a broadening of the rally in 2025 may well be intact.

It certainly seems that investors are confident about stocks closing out 2024 on a high, which is due to a strong underlying economy, earnings growth potential, and the strength of the artificial intelligence trade.

Earnings to watch include Dell Technologies and CrowdStrike.

Volume is likely to be lower due to the holiday this week, so movement could be sharper because of the lack of liquidity in the market.

The consensus amongst strategists for 2025 is for a roughly 10% gain or more for the broader index. 

2025 will be the third year of the bull market.

The S&P500 surged 24% in 2023, and so far in 2024, the S&P500 is up 25%.

S&P500 predictions for the end of 2025

Goldman Sachs = 6,500

Morgan Stanley = 6,500

UBS – 6,400

BMO Capital = 6,700

 

WILL GOOGLE BE FORCED TO SELL OFF CHROME?

Google and other tech giants’ dominance of the internet and search has been under the microscope of American authorities in recent years.

In August this year, a judge ruled Alphabet had a monopoly over online search and related ads.

District Judge Mehta agreed with the US Department of Justice (DOJ) that Google broke the law by paying $41 billion to ensure it was the default search engine on smartphones and browsers.

Recently, the DOJ asked the same judge to force Google to sell Chrome due to its market dominance.

They say the company should also share data and search results with rival browsers like Edge, Firefox, or Safari.

The DOJ’s court filing accuses Google of “unlawful behaviour” by trying to prevent rivals from being able to get a foothold in the market.

Like many countries, the U.S. has “antitrust” laws, which allow the government to break up monopolies and large corporations through the court.

If Judge Mehta rules in favour of all the DOJ’s demands, it would mean:

# Google would be forced to sell Chrome

# It would be banned from releasing a new web browser for five years.

# If competition doesn’t improve, Google will have to sell its Android operating system for smartphones.

# Google would be banned from paying billions of dollars to companies like Apple to make itself the default search engine on their devices.

Of course, this is unlikely to happen overnight, as experts say Google has the option to appeal any rulings.

We also need to consider the new administration and its stance on Big Tech.

Regardless of the position they take, experts say it’s unlikely Judge Mehta will agree with all the DOJ’s demands.

If Google is forced to sell Chrome, who would be the buyer?  At around $US15 billion, they would need deep pockets.  My thinking here - US-based artificial intelligence players.

And what would this mean for the internet?  We are likely to see more innovation and competition in the web browser market. 

 

MARKET UPDATE

S&P500 – Bull run to continue

As I said last week, we are watching the 5,697 level.  Any significant break below that level could take the market back to around 5,400 in the short to medium term and then extend to 5,120.

But let’s work with what we see in front of us now.  We are extending in this 5th wave, and there may be a likelihood that this wave stretches to around 5,465.

Support = ~5925/5890

Immediate resistance = ~6,017/6085

GOLD – Uptrend to persist

We should see gold continuing to advance.  The recent correction/consolidation was well overdue.  Recently, I did recommend taking some profits (scale out/take a % off the table) to lock in some profits.  This provides some income (if you don’t do LEAPS/options) while still holding positions in your portfolio.  In other words, you are taking a little bit of profit - 10%-25% – but you are still left with a healthy investment in your stock/s to allow for growth.

Short term Support = $2,675

Next Target = $2,820

BITCOIN – Rally to continue

The uptrend in Bitcoin is still intact; there are no signs of exhaustion yet.

Very short-term support = ~ $95,650/$94,900/$85,100

Next target = ~$100,600 and then around $109,250

WHAT IS BETA?

Beta is a measure of a company’s stock volatility relative to the overall market.  In other words, you are looking at a company’s stock returns (change in stock price) relative to the overall market returns (change in market stock price).

 

 

QI CORNER

 

 

 

 

SOMETHING TO THINK ABOUT

 

 

 

 

Cheers

Jacquie

https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png 0 0 april@madhedgefundtrader.com https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png april@madhedgefundtrader.com2024-11-25 12:00:082024-11-25 12:25:42November 25, 2024
Page 2 of 14‹1234›»

tastytrade, Inc. (“tastytrade”) has entered into a Marketing Agreement with Mad Hedge Fund Trader (“Marketing Agent”) whereby tastytrade pays compensation to Marketing Agent to recommend tastytrade’s brokerage services. The existence of this Marketing Agreement should not be deemed as an endorsement or recommendation of Marketing Agent by tastytrade and/or any of its affiliated companies. Neither tastytrade nor any of its affiliated companies is responsible for the privacy practices of Marketing Agent or this website. tastytrade does not warrant the accuracy or content of the products or services offered by Marketing Agent or this website. Marketing Agent is independent and is not an affiliate of tastytrade. 

Legal Disclaimer

There is a very high degree of risk involved in trading. Past results are not indicative of future returns. MadHedgeFundTrader.com and all individuals affiliated with this site assume no responsibilities for your trading and investment results. The indicators, strategies, columns, articles and all other features are for educational purposes only and should not be construed as investment advice. Information for futures trading observations are obtained from sources believed to be reliable, but we do not warrant its completeness or accuracy, or warrant any results from the use of the information. Your use of the trading observations is entirely at your own risk and it is your sole responsibility to evaluate the accuracy, completeness and usefulness of the information. You must assess the risk of any trade with your broker and make your own independent decisions regarding any securities mentioned herein. Affiliates of MadHedgeFundTrader.com may have a position or effect transactions in the securities described herein (or options thereon) and/or otherwise employ trading strategies that may be consistent or inconsistent with the provided strategies.

Copyright © 2025. Mad Hedge Fund Trader. All Rights Reserved. support@madhedgefundtrader.com
Scroll to top